NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis $2.12 +0.02 (+0.71%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Silo Pharma Stock (NASDAQ:SILO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silo Pharma alerts:Sign Up Key Stats Today's Range$2.05▼$2.1950-Day Range$2.10▼$7.7352-Week Range$2.05▼$15.15Volume8,822 shsAverage Volume191,832 shsMarket Capitalization$3.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Silo Pharma, Inc. (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health. The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents. Key initiatives include research into treatments for chemotherapy-induced neurotoxicity, glioblastoma, neurodegenerative disorders and mood conditions such as depression and post-traumatic stress disorder. Silo Pharma leverages strategic collaborations and material licensing agreements with leading academic institutions to accelerate its research efforts. Originally founded as Elicio Therapeutics in 2019, the firm rebranded to Silo Pharma in 2021 to underscore its specialized focus on psychedelics and novel CNS therapies. In addition to its U.S. operations, the company engages in collaborative research activities with partners in Canada and Europe. Silo Pharma’s leadership team brings together expertise in pharmaceutical R&D, regulatory strategy and business development to position the company for growth in the emerging psychedelics sector.AI Generated. May Contain Errors. Read More Silo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreSILO MarketRank™: Silo Pharma scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSilo Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSilo Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Silo Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silo Pharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silo Pharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.17% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently decreased by 59.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.22 News SentimentSilo Pharma has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Silo Pharma this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders3.63% of the stock of Silo Pharma is held by insiders.Percentage Held by Institutions5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SILO Stock News HeadlinesSilo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation ForumSeptember 9 at 12:53 PM | rttnews.comSilo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 DevelopmentSeptember 9 at 9:31 AM | quiverquant.comQPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.September 11 at 1:00 AM | Porter & Company (Ad)Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation ForumSeptember 9 at 9:15 AM | globenewswire.comSilo Pharma Gets Canadian Patent Allowance for Stress Disorder TreatmentAugust 20, 2026 | finance.yahoo.comSilo Pharma Acquires Digital Assets via Stock IssuanceAugust 19, 2026 | tipranks.comSilo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD TreatmentAugust 18, 2026 | globenewswire.comSilo Pharma Granted European Patent Covering Novel PTSD TherapyAugust 10, 2026 | markets.businessinsider.comSee More Headlines SILO Stock Analysis - Frequently Asked Questions How have SILO shares performed this year? Silo Pharma's stock was trading at $5.10 at the beginning of 2026. Since then, SILO stock has decreased by 58.8% and is now trading at $2.10. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.44. Silo Pharma had a negative trailing twelve-month return on equity of 81.75% and a negative net margin of 6,726.39%. When did Silo Pharma's stock split? Silo Pharma shares reverse split on Wednesday, June 3rd 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 2nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX). Company Calendar Last Earnings8/13/2026Today9/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, SILO's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SILO CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.23 million Net Margins-6,726.39% Pretax Margin-8,283.33% Return on Equity-81.75% Return on Assets-66.35% Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$70 thousand Price / Sales49.18 Cash FlowN/A Price / Cash FlowN/A Book Value$7.10 per share Price / Book0.30Miscellaneous Outstanding Shares1,590,000Free Float1,530,000Market Cap$3.44 million OptionableNot Optionable Beta0.66 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:SILO) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe IRA Mistake That Could Cost Americans 55+ Thousands in 2026JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silo Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
